reports
Cellectar Biosciences Presented Promising Preclinical Data in Poster P...
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that ...
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
GWRS INC.
AROC GLOBAL WATER RESOURCES
ZIVO ARCHROCK INC.
CPSH ZIVO BIOSCIENCE
FUND INC.
ARVN CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
BCDA INC.
SAVA ARVINAS HOLDING
DX FIRST GUARANTY BANCSHARES
AOUT BIOCARDIA
ACET CASSAVA SCIENCES
ALTM DYNEX CAPITAL INC.
CGEM AMERICAN OUTDOOR BRANDS
OPEN INC.
GGZ ADICET BIO INC
IMRX ALTUS MIDSTREAM COMPANY (A)
ABSI CULLINAN ONCOLOGY INC
PEPG OPENDOOR TECHNOLOGIES INC.
MRVL GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
UAMY IMMUNEERING CORP
PRAX ABSCI CORP
LAW PEPGEN INC
MRAI MARVEL BIOSCIENCES CORP
JSPR U S ANTIMONY CORP
BDSX PRAXIS PRECISION MEDICINES INC
SABS CS DISCO INC
MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Milli...
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the company and several institutional investors to exercise certain existing warrants (the “Existing Warrants”) for gross proceeds to the company of approximately $5.8 million prior to deducting placement agent fees and estimated offering expe...
Cellectar Biosciences Announces European Medicines Agency (EMA) Confir...
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 Potential 2027 European Approval and Commercial Launch of Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM FLORHAM PARK, N.J., O...
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
MBIN SMARTSPACE SOFTWARE
AROC MERCHANTS BANCORP
FUND ARCHROCK INC.
ARVN ROYCE FOCUS TRUST
FGBI INC.
BCDA ARVINAS HOLDING
UUU FIRST GUARANTY BANCSHARES
SAVA BIOCARDIA
DX UNIVERSAL SECURITY INSTRUMENTS INC.
AOUT CASSAVA SCIENCES
ALXO DYNEX CAPITAL INC.
ALTM AMERICAN OUTDOOR BRANDS
AMR INC.
OPEN ALX ONCOLOGY HOLDINGS
GGZ ALTUS MIDSTREAM COMPANY (A)
IMRX ALPHA METALLURGICAL RESOURCES INC
ABSI OPENDOOR TECHNOLOGIES INC.
RYAN GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
MRVL ABSCI CORP
BUKS RYAN SPECIALTY GROUP HLDGS INC
OBLG PEPGEN INC
VANI MARVEL BIOSCIENCES CORP
UAMY BUTLER NATIONAL CORP
PRAX OBLONG INC
NCDL VIVANI MEDICAL INC
NEXT U S ANTIMONY CORP
MRAI PRAXIS PRECISION MEDICINES INC
JSPR NUVEEN CHURCHILL DIRECT LENDING CORP
BDSX NEXTSOURCE MATERIALS INC.
SABS MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
Cellectar Biosciences Presented Compelling Data in Oral Session and Pa...
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival FLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the trea...
Immuneering to Discuss Recently Announced Overall Survival Data from P...
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + m...
Immuneering Announces Pricing of $175 Million Underwritten Public Offe...
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering’s Class A common stock on The Nasdaq Gl...
Immuneering Announces Proposed Underwritten Public Offering of Class A...
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the “Offering”). In addition, Immuneerin...
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months i...
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation...
Cellectar and Evestia Clinical Announce Partnership to Support Auger-E...
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist ...
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tav...
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Act...
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and , a leading radiopharmaceutical biotech company, today announced a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical...
Immuneering to Announce Updated Overall Survival Data from Phase 2a Cl...
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 - Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage ...
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targete...
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Tr...
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meet...
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September. Details are as follows: ADC and Novel Conjugates ...
Cellectar Biosciences to Present Data in Poster Presentation at the Am...
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.